Japan's Pharma-Bio Industry Hosts $225 Million of COVID-Related Projects

---

Researched by Industrial Info Resources (Sugar Land, Texas)--To date, Japan has seen more than 628,000 confirmed COVID-19 cases, and more than 10,700 deaths. Although it has secured the largest amount of COVID-19 vaccines in Asia, Japan has inoculated only 2.2% of its population so far, the slowest among wealthy countries, according to Reuters. The government aims to inoculate 36 million elderly Japanese by July.

Japan's Pharma-Bio Industry is ramping up manufacturing capabilities in the global fight against COVID-19. Industrial Info is tracking five projects in Japan's Pharmaceutical & Biotech Industry related to the manufacturing of vaccines and other products to fight COVID-19, with a total investment value of more than $225 million.

Among the projects are the construction of active pharmaceutical ingredient (API) facilities and upgrades to mask-production plants. Subscribers to Industrial Info's Pharmaceutical & Biotech Project Database can click here for a list.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.